Skip to main content
Fig. 6 | Molecular Neurodegeneration

Fig. 6

From: Pioglitazone ameliorates the phenotype of a novel Parkinson’s disease mouse model by reducing neuroinflammation

Fig. 6

Pioglitazone treatment does not affect neurodegeneration or mitochondrial biogenesis. a immunohistochemistry with antibody anti-TH on DAT-cre and Cox10/DAT-cre mice untreated or treated with pioglitazone. Pioglitazone treatment does not affect the neurodegeneration. Red dashed line surrounds the substantia nigra. b western blot performed on striatal protein homogenates of DAT-cre and Cox10/DAT-cre mice untreated (untr) or fed with pioglitazone (PIO), with markers of dopaminergic axons (TH) and mitochondrial markers (VDAC-porin, NDUFB8 (CI subunit), SDHB (CII subunit), UQCRC2 (core2 subunit of CIII), COXI (CIV subunit) and ATPase-α (CV subunit). c mtDNA content measured by qPCR in striatal samples of DAT-cre and Cox10/DAT-cre mice untreated or treated with pioglitazone

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326